September and October are usually the two worst months in the year for the market, and this year isn't going to be the exception. MiMedx closed at the end of August at $7.04, and this morning we are at $7.30. I realize the daily and weekly prices are volatile, but we are holding our own and buying time through a general market correction. I'm satisfied and willing to be patient. This company is making all the right moves here. The stock price will follow in due time.
I know we have a lot of fans of Schwab on this message board, but their analysis of MiMedx is as bad as Suraj.
Efficient Management of Working Capital - Negative [????]
Recent Price Performance versus Market - Negative [????]
Capital Intensity - Negative [????]
Business Geographic Diversification - Negative [????]
Rating Grade D - Underperform - Sell [????]
This equity report card from Schwab is insulting. Schwab has some stocks rated A or B that deserve an F, and others that are just the opposite. I don't know who wrote this report on MiMedx for Schwab, but this person needs some further schooling.
I believe the company has felt in the past that it was necessary to announce quarterly results early to counter the negative and false stories on Seeking Alpha. The stock is acting fine right now, and Analyst Day is coming in a couple of weeks. It would be foolish to assume that no news is bad news now. We are scheduled to get some news in a couple of weeks, and the current quarter hasn't ended yet.
Over 200 salesmen in 2015. Add in the sales to Zimmer and Medtronic, and you know 190 million in revenue is extremely conservative. The company is talking now about international sales too. Revenues in 2015 will be well over 200 million. By my valuation metrics, this stock deserves a 1.5 billion dollar market cap today based off of 2015 revenues, and more than that in the next 90 days.
Analyst day is October 14. Why are you expecting some news announcement with revised guidance now?
You can be certain the analysts will be asking the same questions you might have. I know we all like to think we are unique, but the questions you have posed on this board are the same questions that others have posed as well. If you really have a question which you feel is unique, then I might suggest emailing your question to one of the analysts listed on the company website. They will probably ask your question, if it isn't discussed by the company first. In the meantime, you just saved yourself an airline ticket, and the cost of a hotel room in New York.
" I assume they have 1 on 1's scheduled with key potential and current investors, but I want broad distribution of the idea, and face to face with mgmt is a good thing."
The deals with Medtronic and Zimmer provide very broad distribution of the idea, and more importantly, the products.
This candy character isn't shorting MiMedx. He is a shareholder in Osiris grasping for straws and bashing MiMedx. Unfortunately for him, MiMedx is near a 52 week high while Osiris is closer to a 52 week low. Perhaps our visiting board fool will wake up soon and understand why this is happening, but I doubt it. It sure takes real balls to keep showing up around here when he remains consistently wrong all the time.
I can't wait to hear his new questions, and to see if he maintains his $6 price target in the face of new revenue and profit numbers. Poor Suraj is still bitter that the company did not release to him the names, pay scale, and resumes of all the salesmen working for MiMedx.
All of his questions are always prefaced by "Guys, could you please add some color to". Crayons with bold colors might be appropriate for him. He is certainly going to have to get more creative now to dig up smut for his friends like Richard Pearson and Streetsweeper.
FINRA member firms are required to report their short positions as of settlement on (1) the 15th of each month, or the preceding business day if the 15th is not a business day, and (2) as of settlement on the last business day of the month.* The reports must be filed by the second business day after the reporting settlement date. FINRA compiles the short interest data and provides it for publication on the 8th business day after the reporting settlement date.
Wetting ones britches is a term that should be reserved for the Atlanta Braves!
Did you watch that game last night between the Royals and the A's? That was one of the best games I've seen in 20 years. It is interesting to note that the Royals have a good second baseman named Omar Infante. I believe he played for your Braves until Frank Wren made one of his boneheaded moves and traded him away for Dan Uggla. What a waste of money and talent.
What were the odds in Vegas before the season started of an Orioles vs. Royals series for the American League pennant? Are the Royals now a team of destiny? I'm retired so I just watched that great comeback by the O's. That 8th inning double by Delman Young to clear the bases will define that series. The playoffs this year have been fantastic so far, and exciting to watch!
"I fully expect FDA resolution prior to the presentation next week"
I sure hope traders in the market don't agree with you, or we could be in for a rude surprise. You and others here have linked the Analyst Day to the Transition Letter. I find that foolish. This company has no control over the FDA. You are raising false hopes and expectations that may not be met.